Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Codiak Biosciences Inc (CDAK)

Codiak Biosciences Inc (CDAK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Codiak BioSciences Appoints Lini Pandite, MBChB, MBA to Board of Directors

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has...

CDAK : 18.03 (+3.26%)
Codiak BioSciences to Present at the Virtual William Blair Biotech Focus Conference 2021

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.03 (+3.26%)
Codiak BioSciences Announces the Transition of Benny Sorensen, M.D., Ph.D. to Scientific Advisory Board Member and Clinical Consultant Roles

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.03 (+3.26%)
Flagship Pioneering Closes $3.4 Billion Capital Pool to Drive Continued Breakthrough Innovations in Human Health and Sustainability

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health...

FHTX : 12.72 (+2.50%)
SANA : 25.88 (+5.08%)
SGTX : 5.75 (+1.95%)
AXLA : 3.20 (+2.24%)
CDAK : 18.03 (+3.26%)
EVLO : 6.99 (+3.02%)
KLDO : 5.38 (-1.65%)
MRNA : 434.46 (+1.58%)
RUBY : 20.00 (+2.77%)
MCRB : 6.35 (+16.30%)
Codiak BioSciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Virtual Conference

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.03 (+3.26%)
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.20 (+2.24%)
CDAK : 18.03 (+3.26%)
DNLI : 52.63 (+1.54%)
EVLO : 6.99 (+3.02%)
FHTX : 12.72 (+2.50%)
KLDO : 5.38 (-1.65%)
MCRB : 6.35 (+16.30%)
MRNA : 434.46 (+1.58%)
RUBY : 20.00 (+2.77%)
SANA : 25.88 (+5.08%)
SGTX : 5.75 (+1.95%)
Codiak BioSciences Appoints Anne-Virginie Eggimann, M.Sc., to Board of Directors

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, announced today it has...

CDAK : 18.03 (+3.26%)
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening

, /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental...

AXLA : 3.20 (+2.24%)
CDAK : 18.03 (+3.26%)
DNLI : 52.63 (+1.54%)
EVLO : 6.99 (+3.02%)
FHTX : 12.72 (+2.50%)
KLDO : 5.38 (-1.65%)
MCRB : 6.35 (+16.30%)
MRNA : 434.46 (+1.58%)
RUBY : 20.00 (+2.77%)
SANA : 25.88 (+5.08%)
SGTX : 5.75 (+1.95%)
New Preclinical Data Demonstrate Potential of Codiak's Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced new...

CDAK : 18.03 (+3.26%)
Codiak to Present Preclinical Data Demonstrating Broad Potential Applications for Engineered Exosomes at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting

Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics as a new class of medicines, today announced that...

CDAK : 18.03 (+3.26%)

Barchart Exclusives

Lumber: The Power of "S"
The rise and fall of the lumber market over the last year was historic, with the next move looking to already be under way. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar